Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.71 |
| ▸ | HTR1A | P08908 | 3/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | HTR7 | P34969 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | HTR6 | P50406 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649906 | 0.83 | HTR1A (0.83) | DRD2HTR1AHTR2A | |
| SCHEMBL15064479 | 0.82 | DRD2 (0.98) | DRD2HTR1AHTR2ADRD4HTR2C | |
| SCHEMBL1040205 | 0.82 | DRD2 (1.00) | DRD2HTR1AHTR2ADRD4HTR2C | |
| SCHEMBL6133598 | 0.81 | DRD2 (0.55) | DRD2HTR1AHTR2ASLC6A4HTR7 | |
| SCHEMBL792611 | 0.81 | DRD2 (0.94) | DRD2HTR1AHTR2ADRD4HTR2C | |
| SCHEMBL793141 | 0.81 | DRD2 (1.00) | DRD2HTR1AHTR2ADRD4HTR2C | |
| SCHEMBL5365266 | 0.80 | SLC6A4 (0.69) | DRD2HTR1AHTR2ASLC6A4HTR6 | |
| SCHEMBL7134140 | 0.77 | DRD2 (0.98) | DRD2HTR1AHTR2ADRD4HTR2C | |
| SCHEMBL7455854 | 0.77 | HTR1A (0.60) | DRD2HTR1AHTR2A | |
| SCHEMBL15064296 | 0.77 | DRD2 (0.87) | DRD2HTR1AHTR2ADRD4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | DRD2 2595/4885HTR1A 575/4885HTR2A 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.